The Motley Fool

Can the Woodford Patient Capital Trust help you to retire early?

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

We all know that to retire early, you need to invest wisely for the future. With this in mind, I’m taking a look at two growth-focused investment trusts which could help you to build wealth over the long haul.

Neil Woodford

The Woodford Patient Capital Trust (LSE: WPCT) consistently ranks as one of the most popular investment trusts. It’s run by Neil Woodford, one of the UK’s best-known fund managers, and aims to invest in a mix of exciting, disruptive early-stage and early-growth companies, together with some of his high conviction mid- and large-cap ideas.

5G is here – and shares of this ‘sleeping giant’ could be a great way for you to potentially profit!

According to one leading industry firm, the 5G boom could create a global industry worth US$12.3 TRILLION out of thin air…

And if you click here we’ll show you something that could be key to unlocking 5G’s full potential...

The fund specialises in investing young companies with strong intellectual property propositions, helping them fulfil their growth potential through the deployment of long-term patient capital.

It has in place an innovative fee structure that combines a very low annual management fee of 0.19% with a 15% performance fee on any excess NAV returns over a 10% cumulative hurdle rate per annum, which is subject to a high water mark. This structure aligns the interests of the fund manager with those of its shareholders and makes it a compelling fund pick for anyone looking to invest for the long haul.

Past performance

However, one major cause for concern for prospective investors is the fund’s dismal past performance. Since its inception in April 2015, it has delivered a total net asset value (NAV) loss of 16%, against the FTSE All-Share Index’s gain of 45% over the same period.

It’s still too early to tell whether its recent underperformance is a sign of things to come, given that the fund has had just over three years of operation — but certainly it has made a number of poor stock picks. Woodford suffered some high-profile losses from his biotech bets in Abaco Capital and Circassia, which more than offset gains from winning investments such as Purplebricks.

And following its recent underperformance, shares in the Woodford Patient Capital Trust currently trade at an 11% discount to its NAV.

Small-cap fund

An alternative trust for investors seeking exciting growth potential from innovative companies is the BlackRock Smaller Companies Trust (LSE: BRSC).

The fund’s recent performance is great, with it having delivered a total NAV return of 15% over the past year, against its benchmark performance of just 5%. This demonstrated the good stock selection made by its fund managers over the past year, with the fund benefiting from its exposure to pharmaceutical, biotechnology, financial and support service stocks.

The most significant contributors to its performance over the past year were Dechra Pharmaceuticals, Keywords Studios, Robert Walters, and Premier Asset Management.

Track record

Its longer-term track record is just as impressive, the fund having achieved very significant outperformance against its benchmark. In the 10 years to 28 February, the fund has delivered a total NAV return of 264%, against the benchmark’s gain of just 67%.

What’s more, BlackRock Smaller Companies Trust has a strong track record of growing its dividend, with 15 years of consecutive annual dividend increases under its belt.

Looking forward, however, I’m wary about the impact of uncertainty surrounding the UK economy, not least because of Brexit, given its heavy exposure to domestically-focused companies. And following recent strong interest in the fund, shares in it trade at a post-Brexit vote low discount to its NAV of just 8%.

5 Stocks For Trying To Build Wealth After 50

Markets around the world are reeling from the coronavirus pandemic…

And with so many great companies trading at what look to be ‘discount-bin’ prices, now could be the time for savvy investors to snap up some potential bargains.

But whether you’re a newbie investor or a seasoned pro, deciding which stocks to add to your shopping list can be daunting prospect during such unprecedented times.

Fortunately, The Motley Fool is here to help: our UK Chief Investment Officer and his analyst team have short-listed five companies that they believe STILL boast significant long-term growth prospects despite the global lock-down…

You see, here at The Motley Fool we don’t believe “over-trading” is the right path to financial freedom in retirement; instead, we advocate buying and holding (for AT LEAST three to five years) 15 or more quality companies, with shareholder-focused management teams at the helm.

That’s why we’re sharing the names of all five of these companies in a special investing report that you can download today for FREE. If you’re 50 or over, we believe these stocks could be a great fit for any well-diversified portfolio, and that you can consider building a position in all five right away.

Click here to claim your free copy of this special investing report now!

Jack Tang has no position in any of the shares mentioned. The Motley Fool UK has recommended Keywords Studios. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

Our 6 'Best Buys Now' Shares

Renowned stock-picker Mark Rogers and his analyst team at The Motley Fool UK have named 6 shares that they believe UK investors should consider buying NOW.

So if you’re looking for more stock ideas to try and best position your portfolio today, then it might be a good day for you. Because we're offering a full 33% off your first year of membership to our flagship share-tipping service, backed by our 'no quibbles' 30-day subscription fee refund guarantee.

Simply click below to discover how you can take advantage of this.